United States Department of Health and Human Services, Public Health Service, National Institutes of Health.USRDS 1997 Annual Data Report.Bethesda: United States Renal Data System; 1997.
2.
SilberbergJ.S., BarréP.E., PrichardS.S., SnidermanA.D.Impact of left ventricular hypertrophy on survival in end-stage renal disease.Kidney Int.1989; 36: 286–90.
3.
BergstrÖmJ.Nutrition and mortality in hemodialysis.J Am Soc Nephrol.1995; 6: 1329–41.
4.
LowrieE.G., LewN.L.Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities.Am J Kidney Dis.1990; 15: 458–82.
5.
MaiorcaR., CancariniG.C., BrunoriG., CameriniC., ManiliL.Morbidity and mortality of CAPD and hemodialysis.Kidney Int.1993; 42(Suppl 40): S4–l5.
6.
KaysenG.A., RathoreV., ShearerG.E., DepnerT.A.Mechanisms of hypoalbuminemia in hemodialysis patients.Kidney Int.1995; 48: 510–16.
7.
StruijkD.G., KredietR.T., KoomenG.C.M., BoeschotenE.W., AriszL.The effect of serum albumin at the start of continuous ambulatory peritoneal dialysis treatment on patient survival.Perit Dial Int.1994; 14: 121–30.
8.
European Dialysis Transplant Association/European Renal Association Registry Report.Demography of dialysis and transplantation in Europe 1984.Nephrol Dial Transplant.1986; 1: 1–8.
9.
FoleyR.N., ParfreyP.S., HarnettJ.D., KentG.M., MurrayD.C., BarréP.E.Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease.J Am Soc Nephrol.1996; 7: 728–36.
StenvinkelP., HeimbürgerO., TuckC., BerglundL.Apo(a)-isoform size and nutritional status in patients with chronic renal failure.Kidney Int.1998; 53: 1336–42.
12.
WartonB.A., PalmerS.E., SomersK.The myocardium in kwashiorkor.Q J Med.1969; 38: 107–16.
13.
SjÖstrÖmM., WretlindM.L., KarlbergI., EdenE., LundholmK.Ultrastructural changes and enzyme activities for energy production in hearts concomitant with tumor-associated malnutrition.J Surg Res.1987; 42: 304–13.
14.
AnkerS.D., PonikowskiP., VameyS., ChuaT.P., ClarkA.L., Well-PeploeK.M.Wasting as independent risk factor for mortality in heart failure.Lancet.1997; 349: 1050–3.
15.
CianfloneK., VuH., ZhangZ., SnidermanA.D.Effect of albumin on lipid synthesis, apoB100 secretion, and LDL catabolism in human HepG2 cells.Atherosclerosis.1994; 107: 125–35.
16.
CianfloneK., ZhangZ., VuV., Kohen-AramogulR., KalantD., SnidermanA.D.The effect of individual amino acids on apoB100 and Lp(a) secretion by HepG2 cells.J Biol Chem.1996; 271: 29136–45.
17.
KarioK., MatsuoT., KobyasahiH.Heparin cofactor II deficiency in the elderly: Comparison with antithrombin II.Thromb Res.1992; 66: 489–98.
18.
JolesJ.A., Willekes-KoolschijN., KoomansH.A.Hypoal-buminemia causes high blood pressure by increasing red cell lysophosphatidylcholine.Kidney Int.1997; 52: 761–70.
19.
LoweG.D.O., DrummondM.M., LorimerA.R., Hut tonI., ForbesD.C., PrenticeC.R.M.Relation between extent of coronary arterial disease and blood viscosity.Br Med J.1980; 280: 673–4.
20.
BlackburnG.L., GibbonG.W., BotheA., BenottiP.N., HarkenH., McEnaryT.M.Nutritional support in cardiac cachexia.J Thorac Cardiovasc Surg1977; 73: 4889–96.
21.
CarrJ.G., StevensonL.W., WaldenJ.A., HeberD.Prevalence and hemodynamic consequences of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.Am J Cardiol.1989; 63: 709–13.
22.
FreemanL.M., RoubenoffR.The nutrition implications of cardiac cachexia.Nutr Rev.1994; 52: 340–7.
23.
RileyM., ElbornJ.S., McKaneW.R., BellN., StanfordC.S., NichollsD.P.Resting energy expenditure in chronic cardiac failure.Clin Sci.1991; 80: 633–9.
24.
PoehlmanE.T., ScheffersJ., GottliebS.S., FischerM.L., VaitekeviciusP.Increased resting metabolic rate in patients with congestive heart failure.Ann Intern Med.1994; 121: 860–2.
HosenpudJ.D., CampbellS.M., MendelsonD.J.Interleukin-1–induced myocardial depression in an isolated beating heart preparation.J Heart Transplant.1989; 8: 460–4.
30.
YokoyamaT., VacaL., RossenR.D., DuranteW., HazarikaP., MannD.L.Cellular effects of tumor necrosis factor-a in the adult mammalian heart.J Clin Invest1993; 92: 2302–12.
31.
BistrianB.R., SchwartzJ., IstifanN.W.Cytokines, muscle proteolysis and the catabolic response to infection and inflammation.Proc Soc Exp Biol Med.1992; 200: 220–3.
32.
RoubenoffR., RoubenoffR.A., CannonJ.G., KehayiasJ.J., ZhuangH., Dawson-HughesB.Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation.J Clin Invest.1994; 93: 2379–86.
33.
WeingartenH.P.Cytokines and food intake: The relevance of the immune system to the study of ingestive behavior.Neurosci Biobehav Rev.1996; 20: 163–70.
34.
RamadoriG., Van DammeJ., RiederH., MeyerK-HInterleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse.Eur J Immunol.1988; 18: 12544–64.
35.
DoweikoJ.P., NompleggiD.J.The role of albumin in human physiology and pathophysiology. Part III: Albumin and disease states.JPEN J Parenter Enteral Nutr-1991; 15: 476–82.
36.
BárányP., Divino-FilhoJ.C., BergstrÖmJ.High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients.Am J Kidney Dis.1997; 29: 565–8.
37.
KaysenG.A., StevensonF.T., DepnerT.A.Determinants of albumin concentration in hemodialysis patients.Am J Kidney Dis.1997; 29: 658–68.
38.
AlexanderR.W.Inflammation and coronary heart disease.N Engl J Med.1994; 331: 468–9.
39.
HeinrichJ., SchulteH., SchonfeldR., KohlerR., AssmanG.Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain.Thromb Haemost.1995; 73: 373–9.
40.
MendallM.A., PatelL., StrachanD., NorthfieldT.C.Creactive protein and its relation to cardiovascular risk factors: A population based cross section study.BMJ.1996; 312: 1061–5.
41.
RidkerP.M., CushmanM., StampferM.J., TraceyR.P., HennekenC.H.Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy man.N Engl J Med.1997; 336: 973–9.
42.
BiasucciL.M., VitelliA., LiuzzoG., AltamuraS., CaligiuriG., MonacoC.Elevated levels of interleukin-6 in unstable angina.Circulation.1996; 94: 874–7.
43.
DaneshJ., CollinsR., PetoR.Chronic infections and coronary heart disease: Is there a link?Lancet.1997; 350: 430–6.
44.
WilhelmsenL., SvärdsuddK., Korsan-BengtsenK., LarssonB.O., WelinL., TibblinG.Fibrinogen a risk factor for stroke and myocardial infarction.N Engl J Med.1984; 311: 501–5.
45.
HaaberA.B., EidmarkI., JensenT., Feldt-RasmussenB., StrandgaardS.Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure.J Am Soc Nephrol.1995; 5: 1581–4.
46.
BostornA.G., SheminD., LapaneK.L., SutherlandP., NadeauM.R., WilsonP.W.F.Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched casecontrol study.Atherosclerosis.1996; 125: 91–101.
47.
KochM., KutkuhnB., TrenkwalderE., BachD., GrabenseeB., DieplingerH.Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) predict coronary heart disease in hemodialysis patients.J Am Soc Nephrol.1997; 8: 1889–98.
48.
BartensW., NauckM., SchollmeyerP., WannerC.Elevated lipoprotein(a) and fibrinogen levels increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients.Perit Dial Int.1996; 16: 27–33.
49.
TomuraS., NakamuraY., DoiM., AndoR., IdaT., ChidaY.Fibrinogen, coagulation factor VII, tissue plasminogen activator inhibitor-1, and lipids as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.Am J Kidney Dis.1996; 27: 848–54.
50.
HajjarK.A., NachmanR.L.The role of lipoprotein(a) in atherogenesis and thrombosis.Annu Rev Med.1996; 47: 423–42.
51.
WadeD.P., ClarkeJ.G., LindahlD.G.Control regions of the apolipoprotein(a) gene and members of the related plasminogen family.Proc Natl Acad Sci U S A.1993; 90: 1369–73.
52.
MaedaS., AbeA., SeishimaM., KakinoK., NomaA., KawadeM.Transient changes of serum lipoprotein(a) as an acute phase protein.Atherosclerosis.1989; 78: 145–50.
53.
KronenbergF., KÖnigP., NeyerU., AuingerM., PribasnigA.A., LangU.Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with endstage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis.J Am Soc Nephrol1995; 6: 110–20.
54.
CressmanM.D., HeykaR.J., PaganiniE.P., O'NeillJ., SkibinskiC.I., HoffH.F.Circulating lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients.Circulation.1992; 86: 475–82.
55.
KarioK., MatsuoT., KobayashiH., MatsuoM., AsadaR., KoideM.High lipoprotein(a) levels in chronic hemodialysis patients are closely related to the acute phase reaction.Thromb Haemost1995; 74: 1020–4.
56.
ZimmermanJ., HerrlingerS., PruyA., WannerC.Mechanism of high serum lipoprotein(a) in hemodialysis patients [Abstract].J Am Soc Nephrol.1997; 8: 260A.
57.
WannerC., ZimmermanJ., QuaschingT., GalleJ.Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients.Kidney Int.1997; 62(Suppl 62): S53–5.
58.
VallanceP., CollierJ., BhagatK.Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link?Lancet.1997; 349: 1391–2.
HerbelinA., NgyenA., ZingraffJ., UrenaP., DeschampLatschaB.Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha.Kidney Int.1990; 37: 117–25.
61.
HaubitzM., BrunkhorstR., WrengerE., FroeseP., SchultzeM., KochK-MChronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis.Perit Dial Int.1996; 16: 158–62.
62.
BergstrÖmJ., HeirnbürgerO., LindholmB., QureshiA.R.Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients [Abstract].J Am Soc Nephrol.1995; 6: 573.
63.
BolognaR.M., LevineD.M., ParkerT.S., CheigJ.S., SerurD., StenzelK.H.High cytokine levels may mediate the high mortality of hemodialysis (HD) patients with low albumin and/or cholesterol (TC) [Abstract].J Am Soc Nephrol.1995; 6: 573.
64.
HanD.S., NohH.J., ShinS.H., LeeI.H., KangS.W., ChoiK.H.C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis (CAPD) patients.J Am Soc Nephrol.1997; 8: 264A.
65.
IkizlerT.A., HarvellR.L., WingardR.L., ShyrV., HakirnR.M.C-reactive protein (CRP) is a predictor of hospitalization in chronic hemodialysis (HD) patients [Abstract].J Am Soc Nephrol.1997; 8: 195A.
66.
BergstrÖmJ., LindholmB.Malnutrition, cardiac disease and mortality: an integrated point of viewAm J Kidney Dis.1998; 32: 834–41.
